This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, Y. Articles by Phillips, M. I. Search for Related Content PubMed PubMed Citation Articles by Tang, Y. Articles by Phillips, M. I. Related Collections Gene expression Gene regulation Other Treatment Acute myocardial infarction Gene therapy

(Hypertension. 2002;39:695.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Hypoxia Inducible Double Plasmid System for Myocardial Ischemia Gene Therapy

Yi Tang; MaShira Jackson; Keping Qian; M. Ian Phillips

From the Department of Physiology and Functional Genomics, University of Florida (Y.T., K.Q., M.I.P.), Gainesville, Fla; and Xavier University (M.J.), New Orleans, La.

Correspondence to M. Ian Phillips, PhD, DSc, University of Florida, Department of Physiology and Functional Genomics, PO Box 100274, 1600 SW Archer Road, Gainesville, FL 32610. E-mail MIP{at}phys.med.ufl.edu

Coronary artery disease frequently involves repeated bouts of myocardial ischemia. To automatically up-regulate the cardioprotective transgenes under hypoxic ischemia, a "vigilant vector" gene therapy system was developed and tested in a rat embryonic myocardial cell line (H9c2). In the vigilant vector, a hypoxia response element-incorporated promoter was used as a switch to turn on the gene expression in response to hypoxic signal. Furthermore, a novel double plasmid system was designed to elevate the potency of the vigilant vector. Instead of putting the promoter and the reporter gene in the same plasmid (single plasmid system), we separated them into two plasmids: the transactivator plasmid and reporter plasmid (double plasmid system). The hypoxia response element (HRE)-incorporated promoter increased the expression of a chimeric transcription factor consisting of the yeast GAL4 DNA binding domain and the human nuclear (transcription) factor-B (NF-B) p65 activation domain. The powerful chimeric regulator binds specifically to the upstream activating sequence for GAL4 in the reporter plasmid and activates the transcription of the transgene. Our experiments showed that the HRE-mediated expression could quickly increase 2.08±0.75-fold within 6 hours of hypoxia and further augmented 7.12±1.52-fold when the hypoxia condition was prolonged to 24 hours. The hypoxia-inducible double plasmid system dramatically amplified the transgene expression under both hypoxia and normoxia by 412.79±185.27-fold and 205.35±65.44-fold, respectively, relative to the single plasmid system. From these results, we concluded that this hypoxia inducible double plasmid system could be used therapeutically to switch on genes that have proven beneficial effects in myocardial ischemia.

Key Words: hypoxia • myocardial ischemia • transcription • gene therapy

This article has been cited by other articles:

				Y. L. Tang, Y. Tang, Y. C. Zhang, K. Qian, L. Shen, and M. I. Phillips Improved Graft Mesenchymal Stem Cell Survival in Ischemic Heart With a Hypoxia-Regulated Heme Oxygenase-1 Vector J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1339 - 1350. [Abstract] [Full Text] [PDF]

				Y. L. Tang, K. Qian, Y. C. Zhang, L. Shen, and M. I. Phillips A Vigilant, Hypoxia-Regulated Heme Oxygenase-1 Gene Vector in the Heart Limits Cardiac Injury After Ischemia-Reperfusion In Vivo Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 251 - 263. [Abstract] [PDF]

				Y. L. Tang, Y. Tang, Y. C. Zhang, K. Qian, L. Shen, and M. I. Phillips Protection From Ischemic Heart Injury by a Vigilant Heme Oxygenase-1 Plasmid System Hypertension, April 1, 2004; 43(4): 746 - 751. [Abstract] [Full Text] [PDF]